Lactobacillus helveticus R0052 and Bifidobacterium longum R0175: The Psychobiotic Combination

← Back to articles

The probiotic combination of Lactobacillus helveticus R0052 plus Bifidobacterium longum R0175 — sold under the brand names Cerebiome and Probio'Stick by Lallemand Health Solutions — is one of the most-tested "psychobiotic" formulations in the literature. The term psychobiotic, popularised by Dinan, Stanton, and Cryan, refers to live organisms that may confer a mental-health benefit when taken in adequate amounts. The honest framing for this pair: it has a genuine, well-controlled originating trial and a small body of follow-up work, but the effect sizes are modest, the endpoints are often physiological rather than clinical, and the literature is smaller than the marketing suggests. Strain identity matters here — these specific deposit numbers (R0052 and R0175) are what was studied, and a generic "L. helveticus + B. longum" product does not automatically inherit the data.

The originating Messaoudi trial

The foundational paper, by Messaoudi and colleagues in the British Journal of Nutrition (published online 2010, in print 2011), combined a rat study with a human trial. In the clinical arm, 55 healthy volunteers were randomised to 30 days of R0052 + R0175 at a combined 3 × 10⁹ CFU daily or placebo. The probiotic group showed statistically significant reductions on the Hopkins Symptom Checklist (global severity, somatisation, depression, and anger-hostility subscales), on the Hospital Anxiety and Depression Scale, on a coping checklist, and in 24-hour urinary free cortisol. It was a small but well-conducted, double-blind, placebo-controlled study, and it is the reason this combination became a reference psychobiotic. The key limitation is that the participants were healthy — the trial demonstrates effects on stress and distress measures in non-clinical adults, not treatment of a diagnosed disorder.

Follow-up trials: small, mechanistic, and mixed

The follow-up literature is thinner and more cautious than headline summaries imply. The most rigorous recent work comes from a Swedish group who ran double-blind, placebo-controlled, crossover functional-MRI studies in healthy volunteers using a probiotic mixture that included R0175 and R0052 (one study added a third strain). In a 2022 emotional-attention-task study (22 subjects) and a companion 2022 arithmetic-stress-task study, the probiotic subtly altered brain activation and functional connectivity in regions tied to emotional and stress processing — but, tellingly, it did not significantly change salivary cortisol, cognitive performance, or the composition of the faecal microbiota. These are proof-of-concept neuroimaging signals in healthy people, not demonstrations of symptom relief. It is also worth noting what is not firmly established: a frequently cited "trial in depressed patients" (the SANGUT study) was registered and published as a protocol using this combination, and should not be read as a completed positive result.

What the broader depression evidence says

Because the combination-specific clinical data are limited, it helps to zoom out to probiotics for clinical depression generally — where the evidence is still weak. A 2019 systematic review and meta-analysis (Nikolova and colleagues) found only three randomised trials in clinically depressed populations meeting inclusion criteria (229 participants total). It reported an overall positive effect on depressive symptoms, mainly when probiotics were added on top of antidepressants, but the authors explicitly described the evidence base as limited and called for larger trials. The reasonable interpretation is that probiotics — including this pair — may have a small adjunctive effect on mood for some people, but the data fall well short of supporting them as a stand-alone treatment.

Mechanism: gut-brain signalling, plausible but unproven in humans

The proposed mechanisms for R0052 + R0175 are the standard gut-brain-axis candidates: reduced intestinal inflammation and permeability (lowering systemic inflammatory signalling to the brain), vagal afferent signalling, and modulation of the hypothalamic-pituitary-adrenal stress axis, possibly involving gut-derived neuroactive metabolites and precursors of GABA and serotonin. Animal work supports a vagal route for related strains, but in humans the mechanism remains inferential — and the Swedish imaging studies notably found brain changes without measurable shifts in cortisol or stool microbiota, suggesting the pathway is more complex than a simple "more good bacteria, less stress" story. See our gut-brain connection piece.

Dose, form, and practical use

The studied dose is a combined 3 × 10⁹ CFU per day of R0052 + R0175, taken as one sachet or capsule, with or without food. Give it at least four weeks; the originating trial assessed effects at 30 days. Tolerability is good and serious adverse effects were not reported. The sensible positioning is as a low-risk adjunct or a short personal trial for everyday stress or mild, subclinical mood symptoms — not a replacement for psychotherapy, SSRIs, or other first-line care in moderate-to-severe depression or anxiety. As with any probiotic, immunocompromised people and the critically ill should check with a clinician first. See the depression and anxiety condition pages.

Bottom line

R0052 + R0175 is a legitimately studied psychobiotic with a solid originating trial in healthy adults and a handful of small mechanistic follow-ups. But the clinical evidence is modest, much of it is physiological rather than symptom-based, and the broader probiotic-for-depression literature remains weak. Treat it as a reasonable, well-tolerated adjunct with realistic expectations — and insist on the specific strains, since that is what the data actually cover.

Sources

1. Messaoudi M, Lalonde R, Violle N, Javelot H, Desor D, Nejdi A, Bisson JF, Rougeot C, Pichelin M, Cazaubiel M, Cazaubiel JM. "Assessment of psychotropic-like properties of a probiotic formulation (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) in rats and human subjects." Br J Nutr, 2011;105(5):755-764. PMID 20974015. DOI: 10.1017/S0007114510004319.
2. Rode J, Edebol Carlman HMT, König J, Repsilber D, Hutchinson AN, Thunberg P, et al. "Probiotic Mixture Containing Lactobacillus helveticus, Bifidobacterium longum and Lactiplantibacillus plantarum Affects Brain Responses Toward an Emotional Task in Healthy Subjects: A Randomized Clinical Trial." Front Nutr, 2022;9:827182. PMID 35571902. DOI: 10.3389/fnut.2022.827182.
3. Edebol Carlman HMT, Rode J, König J, Repsilber D, Hutchinson AN, Thunberg P, et al. "Probiotic Mixture Containing Lactobacillus helveticus, Bifidobacterium longum and Lactiplantibacillus plantarum Affects Brain Responses to an Arithmetic Stress Task in Healthy Subjects: A Randomised Clinical Trial and Proof-of-Concept Study." Nutrients, 2022;14(7):1329. PMID 35405944. DOI: 10.3390/nu14071329.
4. Nikolova V, Zaidi SY, Young AH, Cleare AJ, Stone JM. "Gut feeling: randomized controlled trials of probiotics for the treatment of clinical depression: Systematic review and meta-analysis." Ther Adv Psychopharmacol, 2019;9:2045125319859963. PMID 31263542. DOI: 10.1177/2045125319859963.
5. Karakula-Juchnowicz H, Rog J, Juchnowicz D, Łoniewski I, Skonieczna-Żydecka K, Krukow P, et al. "The study evaluating the effect of probiotic supplementation on the mental status, inflammation, and intestinal barrier in major depressive disorder patients using gluten-free or gluten-containing diet (SANGUT study): a 12-week, randomized, double-blind, and placebo-controlled clinical study protocol." Nutr J, 2019;18(1):50. PMID 31472678. DOI: 10.1186/s12937-019-0475-x.